
Dr. Leo Mascarenhas MD
Hematologist (Pediatric) | Pediatric Hematology-Oncology
4650 W Sunset Blvd Los Angeles CA, 90027About
Dr. Leo Mascarenhas is a pediatric hematologist practicing in Los Angeles, CA. Dr. Mascarenhas specializes in treating children that have a blood disease or cancer. Such blood diseases include disorders of red blood cells, white blood cells and/or platelets. The types of cancers that Dr. Mascarenhas treats include leukemias, lymphomas and certain tumors. Dr. Mascarenhas can also treat bleeding disorders in children. Pediatric hematologists can be found in childrens hospitals, community hospitals, university medical centers and more.
Education and Training
St. John's Medical College 1990
Board Certification
PediatricsAmerican Board of PediatricsABP- Pediatric Hematology-Oncology
Provider Details
Clinical Trials
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
- Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
- Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer
- Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
- A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
- Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
- Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
- Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
- Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
- WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
- Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
- Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
- Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
- Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
- Study of Kidney Tumors in Younger Patients
- Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
- Neuropsychological and Behavioral Testing in Younger Patients With Cancer
- Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
- Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
- Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
- Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
- Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
- Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
- Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
- Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
- Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
- Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB or Stage IIIB-IVB Hodgkin Lymphoma
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
- Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
- PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Treatments
- Liver Cancer
- Brain Tumor
- Kidney Cancer
- Bone Cancer
- Ovarian Cancer
- Leukemia
- Testicular Cancer
- Dermal Aesthetics
- Extra Corporeal Shockwave Therapy
Dr. Leo Mascarenhas MD's Practice location
Practice At 4650 W Sunset Blvd
4650 W Sunset Blvd -Los Angeles, CA 90027Get Direction
Dr. Leo Mascarenhas MD's reviews
Write ReviewPatient Experience with Dr. Mascarenhas
Recommended Articles
- Alternative Treatments for Strep Throat
Strep throat is contagious and is serious infection usually caused by streptococcal bacteria. Strep throat causes inflammation or swelling of the tonsils and the mucous membranes, which line the back of your throat. This complication is very common in children and less common in adults.The common...
- Superheroes Unite For Elementary Student Fighting Lymphoma
Anyone diagnosed with cancer knows how terrifying and debilitating the news can be. Now just imagine how horrible an experience it would be for an elementary school student to hear that they have cancer.It is a sad fact that thousands of children are diagnosed with cancer every year, and it is...
- Purpura
PurpuraPurpura refers to purple-colored spots that are usually seen on the skin, including mucous membranes and other organs. It is also called skin hemorrhages or blood spots.Purpura is usually recognized when there is pooling of blood under the skin due to ruptured small blood vessels. The size of...
- Study Finds 3% of Pediatric Non-Hodgkin Lymphoma Cases Are Transplant Recipients
Lymphoma is a blood cancer that affects both children and adults.Lymphoma begins its growth in the lymphatic white blood cells of the lymph system. This system is a major warrior in fighting off infections and diseases. It is part of the body’s immunity team.The lymph system loops throughout the...
- How Is Leukemia Diagnosed?
Leukemia in its early stages may present no signs or symptoms, as these only appear when the leukemia cells have taken over a large number of normal blood cells. A person with leukemia is very lucky indeed if early-stage detection occurs incidentally, through a routine blood test or one done for...
- Potential Causes of Leukopenia
IntroductionA decrease in the number of white blood cells (WBCs) is referred to as leukopenia. There are several causes for leukopenia. It may be due to certain drugs, cancer, radiation and chemotherapy for cancer, stem cell transplant, surgery, steroids, or autoimmune disorders. The immune system...
Nearby Providers
- Dr. Thomas D Coates MD4650 W Sunset Blvd Los Angeles CA 90027
- Ms. Judith Sato MD1500 E Duarte Rd Duarte CA 91010
- Dr. Theodore Bruce Moore M.D.10833 Le Conte Ave Los Angeles CA 90095
- Dr. Malcolm Brenner MD5400 Balboa blvd Encino CA 91316
- Dr. Edward D Gomperts MD4650 W Sunset Blvd Los Angeles CA 90027
- Dr. Marcio Henrique Malogolowkin MD4650 W Sunset Blvd Los Angeles CA 90027
Nearest Hospitals
KAISER FOUNDATION HOSPITAL - LOS ANGELESl
4867 SUNSET BLVD LOS ANGELES CA 90027HOLLYWOOD PRESBYTERIAN MEDICAL CENTERl
1300 N VERMONT AVE LOS ANGELES CA 90027